Apellis Pharmaceuticals Ownership
| APLS Stock | USD 30.39 0.92 3.12% |
Shares in Circulation | First Issued 2014-09-30 | Previous Quarter 123.9 M | Current Value 123.9 M | Avarage Shares Outstanding 70.7 M | Quarterly Volatility 36.7 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Apellis |
Apellis Stock Ownership Analysis
About 14.0% of the company shares are held by company insiders. The company recorded a loss per share of 2.03. Apellis Pharmaceuticals had not issued any dividends in recent years. Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts. Apellis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 476 people. For more info on Apellis Pharmaceuticals please contact the company at 617 977 5700 or go to https://www.apellis.com.Besides selling stocks to institutional investors, Apellis Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Apellis Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Apellis Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Apellis Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Apellis Pharmaceuticals Insider Trades History
About 14.0% of Apellis Pharmaceuticals are currently held by insiders. Unlike Apellis Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Apellis Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Apellis Pharmaceuticals' insider trades
Apellis Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Apellis Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Apellis Pharmaceuticals backward and forwards among themselves. Apellis Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Apellis Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | T. Rowe Price Investment Management,inc. | 2024-09-30 | 3 M | Fmr Inc | 2024-09-30 | 2.9 M | Siren, L.l.c. | 2024-09-30 | 2.2 M | Assenagon Asset Management Sa | 2024-09-30 | 2.1 M | Jennison Associates Llc | 2024-09-30 | 1.8 M | Geode Capital Management, Llc | 2024-09-30 | 1.8 M | Deutsche Bank Ag | 2024-09-30 | 1.7 M | Boxer Capital Llc | 2024-09-30 | 1.7 M | Fiera Capital Corporation | 2024-09-30 | 1.4 M | Wellington Management Company Llp | 2024-09-30 | 15.6 M | Ecor1 Capital, Llc | 2024-09-30 | 11.9 M |
Apellis Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Apellis Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Apellis Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Apellis Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Apellis Pharmaceuticals Outstanding Bonds
Apellis Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Apellis Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Apellis bonds can be classified according to their maturity, which is the date when Apellis Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Apellis Pharmaceuticals Corporate Filings
F4 | 30th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 10th of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
13A | 22nd of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.